Browsing
     by title


0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

or enter first few letters:   
OK
Full Text
Peer Reviewed
See detailNebulized Anti-IL-13 Monoclonal Antibody Fab' Fragment Reduces Allergen-Induced Asthma
Hacha, Jonathan ULg; Tomlinson, K; Maertens, Ludovic ULg et al

in American Journal of Respiratory Cell and Molecular Biology (2012), sous presse

Rationale: Interleukin-13 (IL-13) is a prototypic Th2 cytokine and a central mediator of the complex cascade of events leading to asthmatic phenotype. Indeed, IL-13 plays key roles in IgE synthesis ... [more ▼]

Rationale: Interleukin-13 (IL-13) is a prototypic Th2 cytokine and a central mediator of the complex cascade of events leading to asthmatic phenotype. Indeed, IL-13 plays key roles in IgE synthesis, bronchial hyperresponsiveness, mucus hypersecretion, subepithelial fibrosis and eosinophil infiltration. Objectives: We assessed the potential efficacy of inhaled anti-IL-13 monoclonal antibody Fab' fragment on allergen-induced airway inflammation, hyperresponsiveness and remodeling in an experimental model of allergic asthma. Anti-IL-13 Fab' was administered to mice as a liquid aerosol generated by inExpose® inhalation system in a tower allowing a nose-only exposure. Methods: BALB/c mice were treated by PBS, anti-IL-13 Fab' or A33 Fab' fragment and subjected to ovalbumin (OVA) exposure for 1 and 5 weeks (short term (ST) and long term (LT) protocols). Measurements and Main Results: Our data demonstrate a significant anti-asthma effect following nebulization of anti-IL-13 Fab' in a model of asthma driven by allergen exposure as compared to saline and non-immune Fab fragments. In short and long terms protocols, administration of the anti-IL-13 Fab' by inhalation significantly decreased bronchial responsiveness to methacholine, BALF eosinophilia, inflammatory cell infiltration in lung tissue, and many features of airway remodeling. Levels of pro-inflammatory mediators and matrix metalloprotease levels were significantly lower in lung parenchyma of mice treated with anti-IL-13 Fab'. Conclusions: These data demonstrate that an inhaled anti-IL-13 Fab' significantly reduces airway inflammation, hyperresponsiveness and remodeling. Specific neutralization of IL-13 in the lungs using an inhaled anti-IL-13 Fab' could represent a novel and effective therapy for the treatment of asthma. [less ▲]

Detailed reference viewed: 103 (9 ULg)
See detailUne nécessaire formation des enseignants-chercheurs ?
Poumay, Marianne ULg

Scientific conference (2011, March 21)

Detailed reference viewed: 6 (0 ULg)
Full Text
See detailLa nécessité d'un inventaire du patrimoine culturel immatériel
Lempereur, Françoise ULg

in Géants d'ici et d'ailleurs (2012, January), (6-7), 24-30

Destinée essentiellement aux institutions et groupements qui ont en charge la sauvegarde du patrimoine culturel immatériel, cette présentation rapide justifie l'inventorisation de ce patrimoine, en ... [more ▼]

Destinée essentiellement aux institutions et groupements qui ont en charge la sauvegarde du patrimoine culturel immatériel, cette présentation rapide justifie l'inventorisation de ce patrimoine, en définit les responsabilités et propose une méthodologie de collectage et de mise à disposition publique des contenus [less ▲]

Detailed reference viewed: 67 (7 ULg)
See detailLa nécessité de banques faunistiques et leur utilisation en Belgique.
Dufrêne, Marc ULg

in Revue d’entomologie du Québec (1992), 37

Detailed reference viewed: 3 (0 ULg)
Full Text
See detailNécessité de nouveaux critères de remboursement pour traiter l'ostéoporose en Belgique
Bruyère, Olivier ULg; Bergmann, Pierre; Body, Jean-Jacques et al

in Ortho-Rhumato (2012), 10(5), 3

Detailed reference viewed: 29 (4 ULg)
Full Text
See detailNécessité des études paléoécologiques pour une gestion raisonnée des tourbières hautes
Hindryckx, Marie-Noëlle ULg; Damblon, Freddy; Schumacker, René ULg

in Région wallonne, conservation de la nature (Ed.) colloque "Gérer la nature?" travaux n° 15 (1990)

A l'exemple des Hautes Fagnes, nous proposons de se baser sur une série d'études paléoécologiques pour entreprendre une gestion raisonnée des tourbières : cartographie et études comparatives de la ... [more ▼]

A l'exemple des Hautes Fagnes, nous proposons de se baser sur une série d'études paléoécologiques pour entreprendre une gestion raisonnée des tourbières : cartographie et études comparatives de la végétation et de son évolution; études hydrologiques de nappes et études paléoécologiques (pollens, macrorestes végétaux, charbons, taux d'humification et datations). Quelques pistes de solutions à la dégradation des tourbières hautes sont proposées. [less ▲]

Detailed reference viewed: 43 (3 ULg)
Full Text
See detailNécessité et utopie
Campus, Ferdinand ULg

Speech/Talk (1951)

Detailed reference viewed: 15 (5 ULg)
See detailNécessité logique et nécessité réelle. Le concept de loi chez Windelband et Rickert
Dewalque, Arnaud ULg

Scientific conference (2005, January 28)

A travers les concepts de "Sollen" et de "Müssen", les néokantiens Heinrich Rickert et Wilhelm Windelband ont tenté de thématiser la distinction entre deux formes de nécessité: la nécessité logique (qui ... [more ▼]

A travers les concepts de "Sollen" et de "Müssen", les néokantiens Heinrich Rickert et Wilhelm Windelband ont tenté de thématiser la distinction entre deux formes de nécessité: la nécessité logique (qui se manifeste notamment dans le fait de "devoir juger") et la nécessité réelle (qui se manifeste dans les lois naturelles). [less ▲]

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailNecessity of phenotypic classification of inflammatory bowel disease.
Louis, Edouard ULg; VAN KEMSEKE, Catherine ULg; Reenaers, Catherine ULg

in Best practice & research. Clinical gastroenterology (2011), 25 Suppl 1

Inflammatory bowel diseases (IBD) are classically divided in Crohn's disease (CD) and ulcerative colitis (UC). However, these two entities are still heterogeneous and a further classification in ... [more ▼]

Inflammatory bowel diseases (IBD) are classically divided in Crohn's disease (CD) and ulcerative colitis (UC). However, these two entities are still heterogeneous and a further classification in subphenotypes is necessary. Clinical subphenotypes are easy to use, do not necessitate complicated tests and can already give very important information for the management of the patients. In CD, clinical subphenotypes are based on age at diagnosis, disease location and disease behaviour. Age at diagnosis allows to differentiating paediatric CD, classical young adult onset and more seldom CD of the elderly. These categories are associated with a different risk of development of complications and disabling disease and may have partly different pathophysiology. The classification on disease behaviour, including stricturin, penetrating or uncomplicated disease may have an impact on reponse to medical treatment and need for surgery. Finally the classification based on location is particularly relevant since it has been associated with different types of complications. Particularly ileal disease has been associated with the risk of surgery and colonic (particularly rectal) disease, with the risk of perianal disease. In UC, the classification in subphenotypes is essentially based on disease location, distinguishing proctitis, left-sided colitis and extensive colitis. This subclassification also has a very significant clinical relevance since extensive colitis has been associated with and increased risk of colon cancer, colectomy and even in some studies, mortality. [less ▲]

Detailed reference viewed: 38 (2 ULg)
See detailNecessity to compare bacterial transcription factor beyond the HTH motif
Rigali, Sébastien ULg

Scientific conference (2003)

Detailed reference viewed: 1 (0 ULg)
See detailNecessity to compare the bacterial transcription factors beyond the HTH motif
Rigali, Sébastien ULg

Scientific conference (2002)

Detailed reference viewed: 3 (1 ULg)
Full Text
Peer Reviewed
See detailNecitumumab plus pemetrexed and cisplatin as first-line therapy in patients with stage IV non-squamous non-small-cell lung cancer (INSPIRE): an open-label, randomised, controlled phase 3 study.
Paz-Ares, Luis; Mezger, Jorg; Ciuleanu, Tudor E. et al

in The Lancet. Oncology (2015), 16(3), 328-37

BACKGROUND: Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed and ... [more ▼]

BACKGROUND: Necitumumab is a second-generation recombinant human immunoglobulin G1 EGFR monoclonal antibody that competitively inhibits ligand binding. We aimed to compare necitumumab plus pemetrexed and cisplatin with pemetrexed and cisplatin alone in patients with previously untreated, stage IV, non-squamous non-small-cell lung cancer (NSCLC). METHODS: We did this randomised, open-label, controlled phase 3 study at 103 sites in 20 countries. Patients aged 18 years or older, with an Eastern Cooperative Oncology Group (ECOG) performance status of 0-2 and adequate organ function, were randomly assigned 1:1 to treatment with a block randomisation scheme (block size of four) via a telephone-based interactive voice-response system or interactive web-response system. Patients received either cisplatin 75 mg/m(2) and pemetrexed 500 mg/m(2) on day 1 of a 3-week cycle for a maximum of six cycles alone, or with necitumumab 800 mg on days 1 and 8. Necitumumab was continued after the end of chemotherapy until disease progression or unacceptable toxic effects. Randomisation was stratified by smoking history, ECOG performance status, disease histology, and geographical region. Patients and study investigators were not masked to group assignment. The primary endpoint was overall survival. Efficacy analyses were by intention to treat. This trial is registered with ClinicalTrials.gov, number NCT00982111. FINDINGS: Between Nov 11, 2009, and Feb 2, 2011, we randomly assigned 633 patients to receive either necitumumab plus pemetrexed and cisplatin (n=315) or pemetrexed and cisplatin alone (n=318). Enrolment was stopped on Feb 2, 2011, after a recommendation from the independent data monitoring committee. There was no significant difference in overall survival between treatment groups, with a median overall survival of 11.3 months (95% CI 9.5-13.4) in the necitumumab plus pemetrexed and cisplatin group versus 11.5 months (10.1-13.1) in the pemetrexed and cisplatin group (hazard ratio 1.01 [95% CI 0.84-1.21]; p=0.96). The incidence of grade 3 or worse adverse events, including deaths, was higher in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed and cisplatin group; in particular, deaths regarded as related to study drug were reported in 15 (5%) of 304 patients in the necitumumab group versus nine (3%) of 312 patients in the pemetrexed and cisplatin group. Serious adverse events were likewise more frequent in the necitumumab plus pemetrexed and cisplatin group than in the pemetrexed and cisplatin group (155 [51%] of 304 vs 127 [41%] of 312 patients). Patients in the necitumumab plus pemetrexed and cisplatin group had more grade 3-4 rash (45 [15%] of 304 vs one [<1%] of 312 patients in the pemetrexed and cisplatin alone group), hypomagnesaemia (23 [8%] vs seven [2%] patients), and grade 3 or higher venous thromboembolic events (23 [8%] vs 11 [4%] patients) than did those in the pemetrexed and cisplatin alone group. INTERPRETATION: Our findings show no evidence to suggest that the addition of necitumumab to pemetrexed and cisplatin increases survival of previously untreated patients with stage IV non-squamous NSCLC. Unless future studies identify potentially useful predictive biomarkers, necitumumab is unlikely to provide benefit in this patient population when combined with pemetrexed and cisplatin. FUNDING: Eli Lilly and Company. [less ▲]

Detailed reference viewed: 45 (0 ULg)
Full Text
Peer Reviewed
See detailThe neck domain of myosin V
Terrak, Mohammed ULg; Staford, Walter; Lu, Renne

in Biophysical Journal (2004), 86

Detailed reference viewed: 10 (4 ULg)
Full Text
See detailNecopinato doni laetissima oblatio
Gerkens, Jean-François ULg

Speech/Talk (2014)

Detailed reference viewed: 14 (1 ULg)
See detailNécrologie : Dominique Keiffer
Kurth, Godefroid ULg

in Revue de l'Instruction Publique en Belgique (1902)

Detailed reference viewed: 14 (4 ULg)
Full Text
Peer Reviewed
See detailNécrologie d'Emmanuel Closset
George, Philippe ULg

in Bulletin de l'Institut Archéologique Liégeois (in press)

Detailed reference viewed: 20 (0 ULg)
Full Text
Peer Reviewed
See detailNécrologie de Rita Lejeune (1906-2009)
Henrard, Nadine ULg

in Estudis Romànics (2011), 33

Detailed reference viewed: 60 (11 ULg)
Full Text
Peer Reviewed
See detailNécrologie Jacques Stiennon (1920-2012)
George, Philippe ULg

in Cahiers de Civilisation Médiévale (2012), 55

Detailed reference viewed: 52 (4 ULg)